The United States Department of Justice has announced that Baylor University Medical Center, Baylor Health Care System and HealthTexas Provider Network (collectively referred to as “Baylor”) have agreed to pay $907,355 to revolve charges that they submitted false claims to Medicare, the Civilian Health and Medical Program of the Uniformed Services and the Federal Employees Health Benefit Program.
Hospices provide individuals who decide not to seek a cure for their medical conditions with treatments aimed at reducing the severity of their symptoms. Medicare beneficiaries are entitled to receive hospice care if they have been diagnosed with six months or less to live. The United States claimed that South Carolina-based Harmony Care Hospice,
Jason Sobek, a former admissions supervisor at Education Management Corporation (“EDMC”), the country’s second-largest operator of for-profit colleges, has filed a lawsuit charging that EDMC’s marketing materials deceived prospective students by falsely inflating job placement statistics. In an interview with ABC News, Mr. Sobek stated that in developing these statistics,
Recent changes to the IRS Whistleblower program are intended to encourage taxpayers to expose tax fraud. The ruling in a recent case, however, revealed the intent of both the IRS and the TAX Court to adhere to existing law. In the matter of Cohen v. Commissioner of Internal Revenue 139 T.C.
Pfizer Inc.’s Wyeth Unit plans to plead guilty to a misdemeanor “misbranding” offense under federal law as part of a $491 million settlement of a government investigation of the company’s promotion of the organ-transplant drug Rapamune. The DOJ has been investigating allegation that Wyeth promoted Rapmune for unauthorized uses and paid kickbacks to doctors.
PHILADELPHIA, PA – Michael A. Morse, a partner in the law firm of Pietragallo Gordon Alfano Bosick and Raspanti, LLP, presented at the Thirteenth Annual Pharmaceutical Regulatory and Compliance Congress and Best Practices Forum in Washington, DC on November 6, 2012. The Compliance Congress is sponsored by the Pharmaceutical Compliance Forum,
The Swiss-based pharmaceutical giant Novartis will pay Texas $19.9 million to settle allegations that it violated the False Claims Act. The whistleblower in this case, Donald Galmines, is a former Novartis marketing representative. Galmines’s suit alleges that the pharmaceutical manufacturer falsely marketed its drug, Elidel, which has been approved by the FDA for use on patients ages two and up who suffer from eczema and who were not seeing results from the “first-line” treatment options.
Boehringer Ingelheim Pharmaceuticals Inc., a Connecticut based pharmaceutical manufacturer, has reached an agreement with the US Government to pay $95 million to resolve allegations relating to the unlawful marketing of three different drugs.
Aggrenox, a stroke-prevention drug, Combivent, a COPD drug and Micardis, a hypertension drug, were all involved in the settlement which alleged that Boehringer improperly marketed these drugs thus causing false claims to be submitted to the government’s health care programs.
A whistleblower suit alleging that office supply giant, Office Depot, was fraudulently overcharging the government for supplies such as pens, ink, furniture and other miscellaneous goods was unsealed late last month. The case claims that the company overcharged government agencies in San Diego County and throughout California under a series of office supply contracts.
A complaint was filed under the Qui Tam Whistleblower Provisions of the Federal False Claims Act alleging that the New York City Department of Education billed Medicaid for Psychological Services given to Special Education students. The government, specifically the US Attorney for the Eastern District, Loretta E. Lynch, announced that the US Government will intervene in this matter.
